Anteris Technologies (ASX:AVR) treats eight more patients in first-in-human THV study

Anteris Technologies (ASX:AVR) has successfully treated eight more patients as part of its ongoing first-in-human DurAVR Transcatheter Heart Valve (THV) study in Tbilisi, Georgia.

Related Keywords

Australia ,Tbilisi ,Georgia General ,Georgia , ,Australian ,Anteri Dur ,Chris Meduri ,Wayne Paterson ,Karl Poon ,Anteris Technologies ,Heart Valve ,Chief Medical Officer Chris Meduri ,Tbilisi Heart ,